Mild transient injection-site reactions causing erythema, itching, pain or swelling occur in 37% vs 10% with placebo. Upper respiratory tract infections 29% vs 16%; headaches 17% vs 13%; rhinitis 12% vs 8%.
The development of autoantibodies has also been detected though the significance of these findings is not known: antinuclear antibodies (11% vs 5% in placebo); anti-dsDNA (15% vs 4%).
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.